CASI PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-48.1M | $-39.3M | $-27.0M | $-41.0M | $-36.7M | $-48.3M |
| Depreciation & Amortization | $1.2M | $1.3M | $2.5M | $1.2M | $500.0K | $600.0K |
| Depreciation | $1.2M | $1.3M | $2.5M | $1.2M | — | — |
| Amortization | $28.0K | $1.1M | $1.3M | $1.2M | $1.3M | $1.3M |
| Stock-Based Compensation | $3.0M | $1.3M | $7.2M | $7.0M | $7.8M | $7.8M |
| Net Cash from Operating Activities | $-20.8M | $-29.2M | $-20.0M | $-21.1M | $-26.8M | $-25.9M |
| Investing Activities | ||||||
| Capital Expenditures | $16.0K | $223.0K | $204.0K | $5.6M | $8.9M | $1.5M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $951.0K | $11.2M | $-9.7M | $31.2M | $-20.7M | $-20.7M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | $278.0K | $3.3M | — | — |
| Net Cash from Financing Activities | $11.3M | $15.4M | $-907.0K | $-3.3M | $29.6M | $47.2M |
| Net Change in Cash | $-7.8M | $-3.6M | $-30.0M | $8.4M | $-18.4M | $3.4M |
| Free Cash Flow | $-20.8M | $-29.4M | $-20.2M | $-26.7M | $-35.8M | $-27.4M |